AUTHORS
Maria Rita Khouri, MD, Hagop Kantarjian, MD2, Hannah Goulart, MD3, Nitin Jain, MD4, Farhad Ravandi, MD5, Kelly Sharon Chien, MD6, Guillermo Montalban-Bravo, MD7, Hussein Ali Abbas, MD, PhD8, Naval Daver, MD9, Tapan Kadia I, MD10, Abhishek Maiti, MBBS11, Maro Ohanian, DO12, Koichi Takahashi, MD,PhD13, Yesid Alvarado Valero, MD14, Gautam Borthakur, MD15, William G. Wierda, MD, PhD16, Jan A. Burger, MD, PhD17, Courtney DiNardo, MD, MSCE18, Alessandra Ferrajoli III, MD19, Fadi G. Haddad, MD20, Danielle Hammond, MD21, Jo Ishizawa, MD, PhD22, Ghayas C. Issa, MD23, Steven Kornblau, MD24, Lucia Masarova, MD25, Naveen Pemmaraju, MD26, Jayastu Senapati, MBBS, MD, DM27, Mahesh Swaminathan, MD28, Musa Yilmaz, MD29, Wuliamatu Deen30, Ejiroghene Mayor31, Rebecca Garris32, Guillermo Garcia-Manero, MD33, Nicholas Short, MD34, Elias Jabbour, MD35
AFFILIATIONS
1 MD Anderson Cancer Center, Houston, Texas, United States
2 MD Anderson Cancer Center, Houston, Texas, United States
3 MD Anderson Cancer Center, Houston, Texas, United States
4 MD Anderson Cancer Center, Houston, Texas, United States
5 MD Anderson Cancer Center, Houston, Texas, United States
6 MD Anderson Cancer Center, Houston, Texas, United States
7 MD Anderson Cancer Center, Houston, Texas, United States
8 MD Anderson Cancer Center, Houston, Texas, United States
9 MD Anderson Cancer Center, Houston, Texas, United States
10 MD Anderson Cancer Center, Houston, Texas, United States
11 MD Anderson Cancer Center, Houston, Texas, United States
12 MD Anderson Cancer Center, Houston, Texas, United States
13 MD Anderson Cancer Center, Houston, Texas, United States
14 MD Anderson Cancer Center, Houston, Texas, United States
15 MD Anderson Cancer Center, Houston, Texas, United States
16 MD Anderson Cancer Center, Houston, Texas, United States
17 MD Anderson Cancer Center, Houston, Texas, United States
18 MD Anderson Cancer Center, Houston, Texas, United States
19 MD Anderson Cancer Center, Houston, Texas, United States
20 MD Anderson Cancer Center, Houston, Texas, United States
21 MD Anderson Cancer Center, Houston, Texas, United States
22 MD Anderson Cancer Center, Houston, Texas, United States
23 MD Anderson Cancer Center, Houston, Texas, United States
24 MD Anderson Cancer Center, Houston, Texas, United States
25 MD Anderson Cancer Center, Houston, Texas, United States
26 MD Anderson Cancer Center, Houston, Texas, United States
27 MD Anderson Cancer Center, Houston, Texas, United States
28 MD Anderson Cancer Center, Houston, Texas, United States
29 MD Anderson Cancer Center, Houston, Texas, United States
30 MD Anderson Cancer Center, Houston, Texas, United States
31 MD Anderson Cancer Center, Houston, Texas, United States
32 MD Anderson Cancer Center, Houston, Texas, United States
33 MD Anderson Cancer Center, Houston, Texas, United States
34 MD Anderson Cancer Center, Houston, Texas, United States
35 MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background
The concomitant chemotherapy-free combination of blinatumomab and ponatinib is an effective frontline approach for adults with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL). Here, we report mature 4-year data, including updated relapse patterns and long-term safety from our phase II study.
Methods
Adults age ≥18 years with newly diagnosed Ph+ B-ALL received up to 5 cycles of blinatumomab with ponatinib 30 mg daily from cycle 1, day 1, reduced to 15 mg daily upon complete molecular response (CMR). Ponatinib was continued for at least 5 years after blinatumomab. Beginning with patient 64, the protocol was amended to increase intrathecal (IT) chemotherapy prophylaxis from 12 to 15 doses to reduce central nervous system (CNS) relapse. Patients with baseline white blood cell (WBC) count >70×10⁹/L received 2 cycles of high-dose methotrexate and cytarabine.
Results
As of July 2026, 88 patients were enrolled. Median age was 53 years (range, 18-84); median baseline WBC count was 15.4×10⁹/L (range, 0.6 - 322). BCR::ABL1 transcripts were p190 in 76% and p210 in 19%. Among 48 patients with single nucleotide polymorphism array testing, 25 (52%) had an IKZF1+ genotype.
The objective response rate (ORR, complete remission [CR] plus CR with incomplete count recovery [CRi]) was achieved in 86/88 (97%), with a CR rate of 95%. Among 72 evaluable patients, next-generation sequencing (NGS)-based measurable residual disease (MRD) negativity was achieved in 69 patients (96%), including 42% after 1 cycle. Major molecular response by BCR::ABL1 transcripts was achieved in 85/88 patients (97%) and complete molecular response (CMR) in 80/88 (91%), including 47/88 (53%) after 1 cycle. Discordance was observed in 13% of patients who were NGS-MRD negative while maintaining low-level BCR::ABL1 transcript positivity.
69 patients (78%) remained in remission without allogeneic stem cell transplantation (SCT); 1 received inotuzumab for MRD positivity and 2 received chimeric antigen receptor (CAR) T-cell therapy for persistent MRD. Two underwent SCT in first remission for persistent p190 transcripts; neither had NGS-MRD clonality established.
Twelve patients (14%) relapsed after a median of 21 months from remission (range, 7-39); 11 had p190 transcripts. Relapses were isolated systemic (n=5; median, 24 months), isolated CNS (n=5; median, 22 months), isolated extramedullary (n=1; 8 months), and combined systemic/CNS (n=1; 17 months). Seven of the 12 pts (58%) had baseline WBC >70×10⁹/L, and 4 died. There were 2 early deaths (1 intracranial hemorrhage from prior chemotherapy; 1 toxic megacolon) and 3 deaths in remission (1 post-procedural bleeding, 1 cerebral aneurysm, 1 respiratory failure). None of the 3 patients with WBC >70×10⁹/L who received high-dose methotrexate and cytarabine have relapsed.
After a median follow-up of 43 months (95% CI, 39-50), the 4-year event-free survival (EFS) and overall survival (OS) rates were 80% and 89%, respectively. EFS (p=0.96) and OS (p=0.22) did not differ between p190 and p210 transcripts. At 4 years, the cumulative incidence of relapse was higher in patients with baseline WBC >70×10⁹/L than in those with WBC ≤70×10⁹/L (45.8% vs 9.3%; p<0.001), whereas death without relapse was similar (0% vs 4.6%; p=0.25). The 4-year cumulative incidence of relapse was 32.8% in patients with IKZF1+ genotype and 13.0% in those without IKZF1+ genotype (p=0.13); corresponding rates of death without relapse were 4.0% and 4.3% (p=0.64).
Treatment-related adverse events included fever/febrile neutropenia (44%), headache (35%), increased alanine aminotransferase (30%), increased lipase (20%), and cytokine release syndrome (20%). Grade ≥3 events included increased lipase (13%), increased alanine aminotransferase (11%), febrile neutropenia (6%), hypertension (5%), venous thrombosis (2%), arterial thrombosis (2%), and coronary artery stenosis (1%). Neurotoxicity included tremor (9%) and immune effector cell-associated neurotoxicity syndrome (1%). Ponatinib was discontinued in 9 patients and dose-reduced in 1.
Conclusion
With mature 4-year follow-up, blinatumomab plus ponatinib continues to produce deep molecular responses and transplant-free remissions in adults with Ph+ B-ALL. Baseline WBC >70×10⁹/L identifies a subgroup with substantially higher relapse risk, supporting evaluation of additional risk-adapted therapy. CNS-directed protocol modifications may reduce CNS relapse; no new safety signals emerged.
DISCLOSURES
Maria Rita Khouri, MD: No relevant conflicts of interest to declare.